Pharmaceuticals and medtech portfolio across immunology, oncology, surgery, and orthopedics.
Data window 5D · 3 evidence documents
JNJ sentiment weakened over the last five sessions as source language around medtech recovery and pharmaceutical pipeline was offset by risk-language acceleration.
The prior baseline was less differentiated, with lower topic momentum and fewer high-importance documents tied to regulatory scrutiny.
Medtech recovery and pharmaceutical pipeline
Litigation reserves and drug pricing pressure
GLP-1, Regulatory scrutiny, GLP-1 capacity and demand durability
Source agreement is generally aligned with price and topic momentum.
Topic-level sentiment, momentum, intensity percentile, risk level, source count, summary, and top source.
Select any source to inspect summary, excerpt, metadata, reliability, and NLP contribution.
Narrative changes around earnings, filings, regulatory events, product updates, and market catalysts.
Sector average sentiment 59 · SPY average sentiment 60
| Ticker | Sentiment | 5D change | Risk | News volume | Primary topic | Regulatory risk | Confidence |
|---|---|---|---|---|---|---|---|
| UNH | 37 | -9.6 pts | Risk 79 | 86 | Regulatory scrutiny | Baseline | High confidence · 82 |
| LLY | 86 | +8.6 pts | Risk 39 | 84 | GLP-1 | Baseline | High confidence · 90 |
| JNJ | 55 | -1.1 pts | Risk 60 | 58 | Regulatory scrutiny | Baseline | Medium confidence · 78 |
Ticker-specific alert feed with source count, driver, suggested workflow, status, and confidence.